Cor Vasa 2026, 68(2):206-211 | DOI: 10.33678/cor.2025.097

Selection of Oral Anticoagulants in Atrial Fibrillation Patients Based on SAMe-TT2R2 Score

Lutfu Askina, Kazim Ersin Altinsoyc, Irfan Yamanc, Veysel Ozgur Barisc, Okan Tanriverdid
a Department of Cardiology, Gaziantep Islamic Science and Technology University, Gaziantep, Turkey
b Department of Emergency Medicine, Gaziantep City Hospital, Gaziantep, Turkey
c Department of Cardiology, Gaziantep City Hospital, Gaziantep, Turkey
d Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey

Clinicians must select between vitamin K antagonists (VKA) like warfarin and non-VKA oral anticoagulants for atrial fibrillation patients. According to observational studies, VKA patients have had international normalised ratio (INR) values outside the time in therapeutic range (TTR < 60%) for a long period of time. Based on common clinical criteria, the SAMe-TT2R2 score may help evaluate whether a VKA will work for a patient. SAMe-TT2R2 scores of 0-1 should perform well on a VKA, whereas values of 2 may result in inadequate TTR. We will examine how consistent the SAMe-TT2R2 score is in selecting oral anticoagulants for atrial fibrilla- tion patients and how recent research reinforces this.

Keywords: SAMe-TT2R2 score, Time in therapeutic range, Vitamin K antagonists

Received: August 31, 2025; Revised: August 31, 2025; Accepted: September 3, 2025; Prepublished online: June 2, 2012; Published: May 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Askin L, Ersin Altinsoy K, Yaman I, Ozgur Baris V, Tanriverdi O. Selection of Oral Anticoagulants in Atrial Fibrillation Patients Based on SAMe-TT2R2 Score. Cor Vasa. 2026;68(2):206-211. doi: 10.33678/cor.2025.097.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
    2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:2246-2280. Go to original source...
    3. Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher? Thromb Haemost 2015;113:1165-1169. Go to original source...
    4. Senoo K, Lau YC, Lip GY. Updated NICE guideline: management of atrial fibrillation. Expert Rev Cardiovasc Ther 2014;12:1037-1040. Go to original source...
    5. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-977. Go to original source...
    6. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-1107. Go to original source...
    7. Sanfélix-Gimeno G, Rodríguez-Bernal CL, Hurtado I, et al. Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol. BMJ Open 2015;5:e007613. Go to original source... Go to PubMed...
    8. Jurcuţ R, Militaru S, Geavlete O, et al. Predictive factors for obtaining a correct therapeutic range using antivitamin K anticoagulants: a tertiary center experience of patient adherence to anticoagulant therapy. Patient Prefer Adherence 2015;9:1271-1278. Go to original source... Go to PubMed...
    9. Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015;113:1170-1173. Go to original source...
    10. Eikelboom JW, Weitz JI. "Real world" use of non-vitamin K antagonist oral anticoagulants (NOACs): lessons from the Dresden NOAC registry. Thromb Haemost 2015;113:1159-1161. Go to original source...
    11. Fauchier L, Poli D, Olshansky B. The SAMe-TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation? Thromb Haemost 2015;114:657-659. Go to original source... Go to PubMed...
    12. Van Den Ham HA, Klungel OH, Leufkens HGM, et al. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 2013;11:107-115. Go to original source...
    13. Sjögren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015;113:1370-1377. Go to original source...
    14. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. Go to original source...
    15. Fauchier L, Angoulvant D, Lip GYH. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015;17:671-673. Go to original source...
    16. Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á, CALIFA study researchers. Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol (Engl Ed) 2015;68:761-768. Go to original source...
    17. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014;8:789-798. Go to original source... Go to PubMed...
    18. Lau YC, Lip GYH. Which drug should we use for stroke prevention in atrial fibrillation? Curr Opin Cardiol 2014;29:293-300. Go to original source... Go to PubMed...
    19. Proietti M, Lip GYH. Simple decision making between a vitamin K antagonist and non-vitamin K antagonist oral anticoagulant (NOACs): using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015;1:150-152. Go to original source... Go to PubMed...
    20. Azoulay L, Dell'Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014;35:1881-1887. Go to original source...
    21. Lip GYH. Stroke prevention in atrial fibrillation: changing concepts. Eur Heart J Cardiovasc Pharmacother. 2015;1:76-79. Go to original source...
    22. Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 2014;103:998-1005. Go to original source...
    23. Menéndez-Jándula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005;142:1-10. Go to original source... Go to PubMed...
    24. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMeTT₂R₂ score. Chest 2013;144:1555-1563. Go to original source...
    25. Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014;9:443-447. Go to original source... Go to PubMed...
    26. Lip GYH, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719-726. Go to original source...
    27. Skov J, Bladbjerg E-M, Bor MV, et al. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014;145:187-188. Go to original source...
    28. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014;127:1083-1088 Go to original source... Go to PubMed...
    29. Abumuaileq RR-Y, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace 2015;17:711-717. Go to original source...
    30. Roldán V, Cancio S, Gálvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective "real-world" inception cohort study. Am J Med 2015;128:1237-1243. Go to original source... Go to PubMed...
    31. Ruiz-Ortiz M, Bertomeu V, Cequier Á, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015;114:695-701. Go to original source...
    32. Lip GYH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. Jama 2015;313:1950-1962. Go to original source...
    33. Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067. Go to original source... Go to PubMed...
    34. Apostolakis SZ, Konstantinides SV. Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. Clin Res Cardiol Suppl 2013;1:38-45. Go to original source...
    35. Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012;307:1952-1958. Go to original source...
    36. Tomita H, Kadokami T, Momii H, et al. Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients. Thromb Res 2013;132:537-542. Go to original source...
    37. Vallurupalli S, Deshmukh A, Paydak H. Gender based differences in benefit from novel oral anticoagulant drugs compared to warfarin in atrial fibrillation: an analysis of published studies. J Am Coll Cardiol 2014;63(12). Go to original source...
    38. Wang KL, Chiang CE. Optimal international normalized ratio for atrial fibrillation in Asians and Japanese: do we really know? Circ J 2013;77:2242-2243. Go to original source... Go to PubMed...
    39. Du M, Li F, Zhang A, et al. Evaluation of ABC Bleeding Score and SAMe-TT2R2 Score on the Risk of Bleeding after Anticoagulation in Patients with Nonvalvular Atrial Fibrillation Complicated with Coronary Heart Disease. Contrast Media Mol Imaging 2022;2022:6982753. Go to original source... Go to PubMed...
    40. Krittayaphong R, Winijkul A, Pirapatdit A, et al. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. Singapore Med J 2020;61:641-646. Go to original source...
    41. Del-Toro-Cervera J, Demelo-Rodriguez P, Galeano-Valle F, et al. Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. Thromb Res 2020;194:178-182. Go to original source...
    42. Zhao J, Zhou D, Chen M, et al. CHA2DS2-VASc and SAMe-TT2R2 scores as predictors of recurrence for nonvalvular atrial fibrillation patients on vitamin K antagonists after radiofrequency catheter ablation. J Cardiovasc Med (Hagerstown) 2020;21:200-208. Go to original source...
    43. Karataş MB, Çanga Y, Yelgeç NS, et al. Modified SAMe-TT2R2 score for predicting the therapeutic range of digoxin. Herz 2021;46:359-366. Go to original source... Go to PubMed...
    44. Alhmoud EN, Elewa H, Abdul Gelil MS, et al. Evaluation of the Validity of SAMe-TT2R2 Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. Clin Appl Thromb Hemost 2020;26:1076029620945039. Go to original source...
    45. Elewa H, Qurishi I, Abouelhassan R, et al. Effect of SAMe-TT2R2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. J Thromb Thrombolysis 2020;49:659-666. Go to original source...
    46. Incomenoy S, Saokaew S, Poonchuay N. SAMe-TT2R2 to Predict Clinical Outcomes and Time in Therapeutic Range in Patients on Vitamin K Antagonists: A Systematic Review and Meta-Analysis. Ann Pharmacother 2024;58:126-139. Go to original source...
    47. Bernaitis N, Clark G, Kohja S, et al. The SAMe-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. J Clin Med 2019;8:882. Go to original source... Go to PubMed...
    48. van Miert JHA, Bos S, Veeger NJGM, et al. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS One 2018;13:e0194208. Go to original source... Go to PubMed...
    49. Hwang AY, Carris NW, Dietrich EA, et al. Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring. Ann Pharmacother 2018;52:1085-1090. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content